



OpGen's Infectious Disease Portfolio Highlighted at IDWeek 2016

October 26, 2016

GAITHERSBURG, Md., Oct. 26, 2016 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced that its infectious disease portfolio will be featured in one oral presentation and 5 poster sessions at IDWeek 2016, which takes place from October 26-30 in New Orleans, LA.

The oral presentation, given by Jacqueline Reuben, Senior Infectious Disease Epidemiologist, District of Columbia Department of Health, will illustrate OpGen's Acuitas Lighthouse[®] MDRO Management System capabilities in a regional prevalence study, called HARP-DC, of multi-drug resistant organisms (MDROs) in Washington, D.C. healthcare facilities. Additional data presented will highlight:

- The company's expertise in informatics and genomic analysis to support the need for preventative frameworks within health facilities.
- OpGen's Acuitas[®] MDRO Gene Test in examining the potential of fecal microbiota transplantation (FMT) to reverse dysbiosis and eliminate colonization with antibiotic-resistant organisms.

"The data presented at IDWeek demonstrate OpGen's commitment to arming hospitals and health systems with the next generation of genomic and informatics solutions to resolve often underestimated infectious disease threats," said Evan Jones, CEO and Chairman of OpGen. "With these data, we are demonstrating our capabilities to assist in the fight against antimicrobial resistance and the importance of implementing effective preventative frameworks across all health systems."

The scheduled times and titles of the poster sessions and presentation are as follows:

Thursday, October 27 from 12:30 PM – 2:00 PM CDT

- Healthcare Antibiotic Resistance Prevalence – DC (HARP - DC) – Measuring the Prevalence of *vanA* genes in Healthcare Facilities (HCFs) in Washington, D.C. (Poster #312 in Poster Hall) presented by Jacqueline Reuben, MHS, District of Columbia Department of Health
- Measuring the Prevalence of Multidrug Resistant Acinetobacter (MDRA) Using *OXA 23 and OXA 51* Gene Identification in Healthcare Facilities (HCFs) in Washington, D.C. (Poster #323 in Poster Hall) presented by Jacqueline Reuben, MHS, District of Columbia Department of Health
- Assessing Carbapenemase Resistant Enterobacteriaceae (CRE) Prevalence Using a Combined Antibiotic Resistance Gene Assay and Surveillance Cultures in Hospitalized Patients (Poster #344 in Poster Hall) presented by Rebecca Kumar, M.D., Georgetown University
- Prevalence of Multi-Drug Resistant Organism (MDRO) Using an Antibiotic Resistant Gene Assay at a Tertiary Care Center (Poster #325 in Poster Hall) presented by Joseph Timpone, M.D., Department of Medicine, Georgetown University

Saturday, October 29 from 12:30 PM – 2:00 PM CDT

- Clearance of Vancomycin-Resistant Enterococcus Colonization with Fecal Microbiota Transplantation among Patients with Recurrent *Clostridium Difficile* Infection (Poster #2119 in Poster Hall) presented by Lindsay Eysenbach, AB, Nonprofit Management Fellow at OpenBiome

Saturday, October 29 at 2:00 PM CDT – Oral Presentation

- Healthcare Antibiotic Resistance Prevalence – DC (HARP - DC)- Measuring the Prevalence of Carbapenem Resistant Enterobacteriaceae in Healthcare Facilities (HCF) in Washington, D.C. (Room 388-390) presented by Jacqueline Reuben, MHS, District of Columbia Department of Health

In addition to these data presentations, initial data from the Intermountain Healthcare retrospective study evaluating the shift in epidemiology in drug resistant organisms over an eight-year period will be presented on Thursday, October 27 at 12:30 p.m. CDT by Dr. Bert Lopansri, lead author of the study at Intermountain Medical Center. He will also host a discussion of the study and its results at the Learning Lounge. The discussion is titled, "Antibiotic resistant bacteria in our Integrated Healthcare Network: are new diagnostic tests needed?" and will take place on Saturday, October 29, 2016 from 1:15 p.m. to 1:45 p.m. CDT at booth #1300.

About OpGen

OpGen, Inc. is harnessing the power of informatics and genomic analysis to provide complete solutions for patient, hospital and network-wide infection prevention and treatment. Learn more at www.opgen.com and follow OpGen on [Twitter](#) and [LinkedIn](#).

Company Contact:

Michael Farmer
Director, Marketing
(240) 813-1284
mfarmer@opgen.com
InvestorRelations@opgen.com

Investor and Media Contact:
MacDougall Biomedical Communications
Cammy Duong
781-235-3060
cduong@macbiocom.com



OpGen, Inc.